Related Experiment Video
Updated: May 6, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
27.4K
Stefan Agewall, Editor-in-Chief of new EHJ Cardiovascular Pharmacotherapy journal
European Heart Journal
|October 23, 2014
Summary
A new journal, European Heart Journal—Cardiovascular Pharmacotherapy, launched in February 2014. It focuses on cardiovascular pharmacotherapy research and clinical practice.
Area of Science:
- Cardiovascular Medicine
- Pharmacotherapy
- Medical Publishing
Background:
- The European Society of Cardiology (ESC) launched a new journal in 2014.
- The journal is titled European Heart Journal—Cardiovascular Pharmacotherapy.
- Publication commenced in February 2014.
Discussion:
- The journal aims to cover advancements in cardiovascular pharmacotherapy.
- It serves as a platform for disseminating research and clinical insights.
- The launch signifies a growing focus on pharmacologic treatments in cardiology.
Key Insights:
- New dedicated journal for cardiovascular pharmacotherapy established.
- European Heart Journal—Cardiovascular Pharmacotherapy commenced publication in early 2014.
- ESC Congress 2014 served as the launch venue.
Outlook:
- The journal is expected to become a key resource for cardiovascular pharmacotherapy.
- It will likely foster innovation and best practices in the field.
- Future publications will shape the understanding and application of cardiovascular drugs.
Related Concept Videos
02:03Anatomy of the Circulatory System
89.0K
The human circulatory system consists of blood, blood vessels that carry blood away from the heart, around the body, and back to the heart, and the heart itself, which acts as a central pump. The systemic circuit supplies blood to the whole body, the coronary circuit supplies blood to the heart, and the pulmonary circuit supplies blood flow between the heart and lungs.
89.0K
01:27Anatomy of the Heart
93.4K
The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
93.4K
01:13The Cardiac Cycle
77.6K
The heart beats rhythmically in a sequence called the cardiac cycle—a rapid coordination of contraction (systole) and relaxation (diastole).
The Process
Electrical signals—sent from the sinoatrial (SA) node in the right atrial wall to the atrioventricular (AV) node between the right atrium and right ventricle—cause both atria to simultaneously contract. When the signal reaches the AV node, it pauses for approximately a tenth of a second, allowing the atria to contract and...
The Process
Electrical signals—sent from the sinoatrial (SA) node in the right atrial wall to the atrioventricular (AV) node between the right atrium and right ventricle—cause both atria to simultaneously contract. When the signal reaches the AV node, it pauses for approximately a tenth of a second, allowing the atria to contract and...
77.6K
01:29Blood Flow
57.5K
Blood is pumped by the heart into the aorta, the largest artery in the body, and then into increasingly smaller arteries, arterioles, and capillaries. The velocity of blood flow decreases with increased cross-sectional blood vessel area. As blood returns to the heart through venules and veins, its velocity increases. The movement of blood is encouraged by smooth muscle in the vessel walls, the movement of skeletal muscle surrounding the vessels, and one-way valves that prevent backflow.
57.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K